Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

The LEAP-010 trial excluded patients with vascular involvement due to the drug's bleeding risk. This is a common characteristic in real-world head and neck cancer patients, especially post-radiation. This discrepancy means that even if the drug combination had been successful, its applicability in routine clinical practice would be severely limited.

A primary obstacle preventing community SCLC patients from joining clinical trials is not their unwillingness, but physicians not offering the option due to assumptions about patient interest or eligibility. The first step to improving enrollment is ensuring the conversation happens.

Clinicians identify outdated control arms—like single-agent chemotherapy without newer targeted agents—as a major deterrent for patient trial participation. Patients are unwilling to be randomized to a therapy that doesn't reflect the current, more effective standard of care. This pressure is forcing sponsors and the FDA to design trials with more realistic comparator arms.

Instead of a total overhaul, we can accelerate trials with three changes: 1) A simple patient opt-in registry for trial participation. 2) Collaborative platform trials testing multiple drugs against one control group. 3) A shared database for all trial data, including failures.

Strict, and sometimes arbitrary, clinical trial eligibility criteria are a key barrier to enrollment. A patient with a GFR of 52 being excluded from a trial requiring a GFR of 60 illustrates how minor, clinically insignificant differences can prevent patients from accessing novel therapies. This highlights a need for more pragmatic and flexible trial inclusion criteria.

Beyond medical side effects, clinical trials impose a significant 'procedural burden' on patients: frequent travel, extra blood draws, and endless questionnaires. This human cost must be minimized, as it can disrupt a patient's life and limit participation for those without strong support systems.

For pancreatic cancer patients, the primary obstacle to receiving promising KRAS-targeted therapies is not drug efficacy but logistical access. There are far more eligible patients than available slots on clinical trials, creating a significant and "tragic" bottleneck in delivering cutting-edge care.

Many clinical trials fail not because the science is wrong, but because of operational issues like patient recruitment and retention. These problems often stem from overly burdensome and rigid trial designs that deter participation, a preventable error.